Puma Biotechnology Inc : Puma Biotechnology Reports Positive Top Line Data …

Puma Biotechnology Inc : Puma Biotechnology Reports Positive Top Line Data …
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced top line results from the Phase II clinical trial of Puma's investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I …
Read more on 4-traders (press release)

Median Technologies signs 3-year deal with US Ph I cancer trial centre
Median CEO Fredrik Brag, explained that: “Our LMS application provides immense value for better assessing oncology patients' response to therapy in clinical trials. The addition of our LMS applications to START's current capabilities will bring …
Read more on OutSourcing-Pharma.com

TherapeuticsMD Inc : TherapeuticsMD Appoints Joel S. Krasnow, M.D. as Chief …
Dr. Krasnow has participated in and directed many IND/NDA/BLA filings, presentations and labeling negotiations resulting in numerous regulatory approvals across therapeutic areas, and has managed clinical and medical marketing programs in women's …
Read more on 4-traders (press release)

AG: Caremark To Pay MassHealth .6M For Not Reimbursing Pharmacy Claims
A company responsible for processing and paying prescription drug claims will pay $ 2.6 million to the Massachusetts Medicaid Program (MassHealth) to settle allegations that the company failed to reimburse MassHealth for pharmacy claims paid on behalf …
Read more on WBUR

Related Drug Treatment Programs In Texas Information…